Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K7FY
|
|||
| Former ID |
DIB007201
|
|||
| Drug Name |
EGF816
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 3 | [1] | |
| Company |
Novartis pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H31ClN6O2
|
|||
| Canonical SMILES |
CC1=NC=CC(=C1)C(=O)NC2=NC3=C(N2C4CCCCN(C4)C(=O)C=CCN(C)C)C(=CC=C3)Cl
|
|||
| InChI |
1S/C26H31ClN6O2/c1-18-16-19(12-13-28-18)25(35)30-26-29-22-10-6-9-21(27)24(22)33(26)20-8-4-5-15-32(17-20)23(34)11-7-14-31(2)3/h6-7,9-13,16,20H,4-5,8,14-15,17H2,1-3H3,(H,29,30,35)/b11-7+/t20-/m1/s1
|
|||
| InChIKey |
IOMMMLWIABWRKL-WUTDNEBXSA-N
|
|||
| CAS Number |
CAS 1508250-71-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.